Skip to Content

'
Christopher H. Crane, M.D.

Present Title & Affiliation

Primary Appointment

Professor with Tenure, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Christopher Crane, M.D., is a Professor, Program Director and Section Chief, Gastrointestinal Section, Residency and Fellowship Program Director, Department of Radiation Oncology at The University of Texas M. D. Anderson Cancer Center. He is the chairman of the Gastrointestinal Committee of the Radiation Therapy Oncology Group. His primary research interest is the combination of novel chemotherapeutic agents with radiotherapy and the investigation of radiation dose escalation in the treatment of gastrointestinal malignancies.

Education & Training

Degree-Granting Education

1993 University of Virginia, Charlottesville, VA, MD, Medicine
1989 University of Miami, Coral Gables, FL, BS, Biology

Postgraduate Training

1996-1998 Chief Resident (2 Years), Radiation Oncology, The University of Virginia, Charlottesville, VA, Dr. Tyvin Rich
1994-1998 Resident, Radiation Oncology, The University of Virginia, Charlottesville, VA, Dr. Tyvin Rich
1993-1994 Transitional Internship, Roanoke Memorial Hospital, Roanoke, VA, Dr. William Ervin

Board Certifications

6/2008 American Board of Radiology

Experience/Service

Administrative Appointments/Responsibilities

Resident and Fellowship Program Director, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/2007-present
Program Director, GI Section, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2003-present
Section Chief, GI Section, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2003-present
Associate Medical Director, Multidisciplinary Gastrointestinal Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2003-present

Other Appointments/Responsibilities

Corresponding Co-Chair, Gastrointestinal Committee, The NRG Oncology Group, Philadelphia, PA, 9/2012-present
Chair, Non-Colorectal GI subcommittee, The NRG Oncology Group, Philadelphia, PA, 9/2012-present
Chairman, GI Committee, Radiation Therapy Oncology Group (RTOG), Philadelphia, PA, 6/2010-present
Member, NCI Gastrointestinal Steering Committee, Bethesda, MD, 6/2010-present
Oral Board Examiner and Written Exam Question Writer, American Board of Radiology, Tucson, AZ, 2004-present

Consultantships

Consultant, Pancreatic Cancer Action Network (PanCAN), United States, 1/2004-present

Institutional Committee Activities

Member, Gastrointestinal Center Steering Committee, 2001-present

Professional Memberships

American Radium Society
Member, 1/1999-present
American Society for Therapeutic Radiology Oncology
Member, 1/1995-present
American Society of Clinical Oncology
Member, 1/2000-present
Gilbert H. Fletcher Society
Secretary, 1/2003-present
Member, 1/1998-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric Bleeding After Radiation Therapy for Intrahepatic Cholangiocarcinoma. Prac Radiat Oncol. In Press.
2. Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 16(5):430-438, 5/2014. e-Pub 8/2013. PMCID: PMC4008161.
3. Katz MH, Crane CH, Varadhachary G. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol 24(2):105-112, 4/2014. PMID: 24635867.
4. Coburn N, Seevaratnam R, Paszat L, Helyer L, Law C, Swallow C, Cardosa R, Mahar A, Lourenco LG, Dixon M, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, McLeod R. Optimal Management of Gastric Cancer: Results From an International RAND/UCLA Expert Panel. Ann Surg 259(1):102-108, 1/2014. e-Pub 3/2013. PMID: 23478525.
5. Brar S, Law C, McLeod R, Helyer L, Swallow C, Paszat L, Seevaratnam R, Cardoso R, Dixon M, Mahar A, Lourenco LG, Yohanathan L, Bocicariu A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, Coburn N. Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. J Am Coll Surg 217(2):347-357.e1, 8/2013. e-Pub 5/2013. PMID: 23664139.
6. Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M, Krishnan S, Delclos ME, Crane CH. Duodenal Toxicity after Fractionated Chemoradiation for Unresectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 85(3):e143-149, 3/1/2013. e-Pub 11/29/2012. PMID: 23200173.
7. Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, Crane CH, Das P. Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy for Anal Cancer: Outcomes and Toxicity. Am J Clin Oncol. e-Pub 3/4/2013. PMID: 23466576.
8. Dixon M, Seevaratnam R, Wirtzfeld D, McLeod R, Helyer L, Law C, Swallow C, Paszat L, Bocicariu A, Cardoso R, Mahar A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, Van de Velde CJ, Wong S, Coburn N. A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer. Ann Surg Oncol 20(2):533-541, 2/2013. e-Pub 9/2012. PMID: 22941158.
9. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749-5756, 12/2012. e-Pub 5/2012. PMID: 22605518.
10. Roland CL, Katz MH, Gonzalez GM, Pisters PW, Vauthey JN, Wolff RA, Crane CH, Lee JE, Fleming JB. A High Positive Lymph Node Ratio is Associated with Distant Recurrence after Surgical Resection of Ampullary Carcinoma. J Gastrointest Surg 16(11):2056-2063, 11/2012. e-Pub 8/2012. PMID: 22914983.
11. Abbott DE, Merkow RP, Cantor SB, Fleming JB, Varadhachary GR, Crane C, Bentrem DJ, Bilimoria KY. Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement. Ann Surg Oncol 19(12):3659-3667, 11/2012. e-Pub 9/2012. PMID: 22965567.
12. Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, Reyes-Gibby CC, Bedi D, Bruera E. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage 44(2):181-191, 8/2012. e-Pub 6/2012. PMID: 22695045.
13. Briere TM, Crane CH, Beddar S, Bhosale P, Mok H, Delclos ME, Krishnan S, Das P. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients. Radiother Oncol 104(2):161-166, 8/2012. e-Pub 7/26/2012. PMID: 22841019.
14. Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 215(1):41-51; discussion 51-52, 7/2012. e-Pub 5/2012. PMID: 22608401.
15. Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 83(2):581-586, 6/1/2012. e-Pub 12/2/2011. PMID: 22137021.
16. Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH. Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. Ann Surg Oncol 19(6):2045-2053, 6/2012. e-Pub 1/19/2012. PMID: 22258816.
17. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer. J Clin Oncol 30(15):1770-1776, 5/20/2012. e-Pub 4/9/2012. PMCID: PMC3383178.
18. Kelly P, Das P, Varadhachary GR, Fontanilla HP, Krishnan S, Delclos ME, Jhingran A, Eifel PJ, Crane CH. Role of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis. Int J Radiat Oncol Biol Phys 82(5):2012-2017, 4/1/2012. e-Pub 6/2/2011. PMID: 21640510.
19. Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Crane CH, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 36(3):409-417, 3/2012. PMCID: PMC3288807.
20. Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PW, Lee JE, Vauthey JN, Abdalla EK, Wolff R, Abbruzzese J, Varadhachary G, Chopin-Laly X, Charnsangavej C, Fleming JB. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 16(1):68-78; discussion 78-79, 1/2012. e-Pub 11/8/2011. PMID: 22065318.
21. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. Ann Surg Oncol 18(13):3615-3622, 12/2011. e-Pub 6/24/2011. PMID: 21701927.
22. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 29(31):4105-4112, 11/2011. e-Pub 10/2011. PMID: 21969502.
23. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 50(8):1191-1198, 11/2011. e-Pub 7/2011. PMID: 21793641.
24. Vern-Gross TZ, Shivnani AT, Chen K, Lee CM, Tward JD, MacDonald OK, Crane CH, Talamonti MS, Munoz LL, Small W. Survival Outcomes in Resected Extrahepatic Cholangiocarcinoma: Effect of Adjuvant Radiotherapy in a Surveillance, Epidemiology, and End Results Analysis. Int J Radiat Oncol Biol Phys 81(1):189-198, 9/1/2011. e-Pub 10/23/2010. PMID: 20971573.
25. Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW, Eng C, Krishnan S, Maru DM, Das P. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer 117(16):3713-3722, 8/15/2011. e-Pub 2/15/2011. PMCID: PMC3266661.
26. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation with Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma - Correlation of Smad4(Dpc4) Immunostaining with Pattern of Disease Progression. J Clin Oncol 29(22):3037-3043, 8/1/2011. e-Pub 6/27/2011. PMCID: PMC3157965.
27. Tan CH, Bhosale PR, Das P, Crane CH, Viswanathan C, Raval B, Eng C, Iyer RB. Multidetector Computed Tomography Follow-up of Hypoattenuating Small Liver Lesions in Patients With Rectal Cancer. Am J Clin Oncol 34(4):411-416, 8/2011. e-Pub 8/2010. PMID: 20686401.
28. Tamm EP, Loyer EM, Faria S, Raut CP, Evans DB, Wolff RA, Crane CH, Dubrow RA, Charnsangavej C. Erratum to: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging. e-Pub 2/25/2011. PMID: 21350817.
29. Mok H, Crane CH, Palmer MB, Briere TM, Beddar S, Delclos ME, Krishnan S, Das P. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 6:63, 2011. e-Pub 6/8/2011. PMCID: PMC3121606.
30. Silberfein EJ, Kattepogu KM, Hu C-Y, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Ann Surg Oncol 17:2863-2869, 6/2010.
31. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CH. Hyperfractionated Accelerated Radiotherapy for Rectal Cancer in Patients with Prior Pelvic Irradiation. Int J Radiat Oncol Biol Phys 77(1):60-65, 5/2010. e-Pub 8/2009. PMID: 19695792.
32. Crane CH, Varadhachary GR, Wolff RA, Fleming JB. Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy. Ann Surg Oncol 17(4):950-952, 4/2010. e-Pub 12/2009. PMCID: PMC2840675.
33. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation. Dig Dis Sci 55(4):1098-1105, 4/2010. e-Pub 4/28/2009. PMID: 19399614.
34. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 76(3):824-830, 3/1/2010. e-Pub 5/21/2009. PMID: 19464823.
35. Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CH. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 116(4):822-829, 2/15/2010. PMID: 20041481.
36. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB. Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation. Ann Surg Oncol. e-Pub 2/17/2010. PMID: 20162463.
37. Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, Delclos ME, Feig BW. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol 17(2):441-447, 2/2010. e-Pub 10/22/2009. PMCID: PMC3076509.
38. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage 38(6):894-902, 12/2009. PMCID: PMC2795073.
39. Hodges JC, Das P, Eng C, Reish AG, Beddar AS, Delclos ME, Krishnan S, Crane CH. Intensity-Modulated Radiation Therapy for the Treatment of Squamous Cell Anal Cancer with Para-Aortic Nodal Involvement. Int J Radiat Oncol Biol Phys 75(3):791-794, 11/2009. e-Pub 2/2009. PMID: 19231109.
40. Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-Raj S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan S. Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 75(3):775-781, 11/2009. e-Pub 2/2009. PMID: 19231100.
41. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG. Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 27(25):4096-4102, 9/2009. e-Pub 7/2009. PMCID: PMC2734421.
42. Bouchard M, Amos RA, Briere TM, Beddar S, Crane CH. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol 92(2):238-243, 8/2009. e-Pub 5/18/2009. PMID: 19454367.
43. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3):818-823, 7/2009. e-Pub 1/2009. PMID: 19147305.
44. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. Ann Surg Oncol 16(4):836-847, 4/2009. e-Pub 2/5/2009. PMID: 19194760.
45. Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, Gross H, Willett C, Kelsen D. Randomized Phase II Trial Evaluating Two Paclitaxel and Cisplatin-Containing Chemoradiation Regimens As Adjuvant Therapy in Resected Gastric Cancer (RTOG-0114). J Clin Oncol 27(12):1956-1962, 4/2009. e-Pub 3/2009. PMCID: PMC2669761.
46. Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA. The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiother 13(2):123-143, 4/2009. e-Pub 1/23/2009. PMID: 19167921.
47. Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters PW, Evans DB. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg 144(3):216-221, 3/2009. PMID: 19289659.
48. Haque W, Crane CH, Krishnan S, Delclos ME, Javle M, Garrett CR, Wolff RA, Das P. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol 4:55, 2009. PMCID: PMC2787526.
49. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-342, 9/2008. PMID: 18794067.
50. Wang H, Krishnan S, Wang X, Beddar AS, Briere TM, Crane CH, Mohan R, Dong L. Improving soft-tissue contrast in four-dimensional computed tomography images of liver cancer patients using a deformable image registration method. Int J Radiat Oncol Biol Phys 72(1):201-209, 9/2008. PMID: 18722271.
51. Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 15(11):3147-3156, 8/2008.
52. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3487-3495, 8/2008.
53. Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, Ajani JA, Crane CH. Incidence, Natural History, and Patterns of Locoregional Recurrence in Gastric Cancer Patients Treated with Preoperative Chemoradiotherapy. Int J Radiat Oncol Biol Phys 71(3):741-747, 7/2008. e-Pub 12/2007. PMID: 18164837.
54. Yu TK, Bhosale PR, Crane CH, Iyer RB, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Das P. Patterns of Locoregional Recurrence After Surgery and Radiotherapy or Chemoradiation for Rectal Cancer. Int J Radiat Oncol Biol Phys 71(4):1175-1180, 7/2008. e-Pub 1/2008. PMID: 18207667.
55. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative Gemcitabine-based Chemoradiation for Patients with Resectable Adenocarcinoma of the Pancreatic Head. J Clin Oncol 26(21):3496-3502, 7/2008.
56. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833-846; discussion 846-848, 5/2008. PMID: 18471707.
57. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys 71(1):167-172, 5/2008. PMID: 18406886.
58. Krishnan S, Dawson LA, Seong J, Akine Y, Beddar S, Briere TM, Crane CH, Mornex F. Radiation therapy for hepatocellular carcinoma. Ann Surg Oncol 15(4):1015-1024, 4/2008. PMID: 18236114.
59. Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res 2:1-14, 1/2008.
60. Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol 47(3):421-427, 2008. e-Pub 9/2007. PMID: 17899453.
61. Wang X, Krishnan S, Zhang X, Dong L, Briere T, Crane CH, Martel M, Gillin M, Mohan R, Beddar S. Proton Radiotherapy for Liver Tumors: Dosimetric Advantages over Photon Plans. Med Dosim 33(4):259-267, 2008. PMID: 18973852.
62. Gao S, Delclos ME, Tomas LC, Crane CH, Beddar S. High-dose-rate remote afterloaders for intraoperative radiation therapy. AORN J 86(5):827-836; quiz 837-840, 11/2007. PMID: 18050890.
63. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW. Role of Adjuvant Chemoradiation Therapy in Adenocarcinomas of the Ampulla of Vater. Int J Radiat Oncol Biol Phys 70(3):735-743, 10/2007. e-Pub 10/2007. PMID: 17980502.
64. Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, Ajani JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 110(5):989-995, 9/2007.
65. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246(1):52-60, 7/2007.
66. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 68:794-800, 7/2007. PMID: 17379452.
67. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110:47-55, 5/2007. PMID: 17538975.
68. Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C. Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation. J Pain Symptom Manage [Epub ahead of print](3). e-Pub 5/2007.
69. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 109(9):1750-1755, 5/2007. PMID: 17387743.
70. Aloia TE, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Abbruzzese JL, Crane CH, Evans DB, Pisters PW. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 204 (3):347-355, 3/2007. PMID: 17324767.
71. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 14(2):478-483, 2/2007. e-Pub 11/2006. PMID: 17103253.
72. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. Ann Surg Oncol 14(7):2010-2017, 1/2007. PMID: 17253104.
73. Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C Wolff RA, Janjan NA, Krishnan S, Crane CH. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res 1:44-48, 2007.
74. Krishnan S, Lin EH, Gunn GB, Chandra A, Beddar AS, Briere TM, Das P, Delclos ME, Janjan NA, Crane CH. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol 29(6):562-567, 12/2006. PMID: 17148992.
75. Das P, Lin EH, Bhatia S, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Delclos ME, Krishnan S, Janjan NA, Crane CH. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 66:1378-1383, 12/2006. PMID: 17056196.
76. Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S, Varadhachary G, Evans DB, Wolff RA, Crane CH. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107(11):2589-2596, 12/2006. PMID: 17083124.
77. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66(3):762-771, 11/2006. PMID: 17011451.
78. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 107(7):1475-1482, 10/2006. PMID: 16944539.
79. Tamm EP, Loyer EM, Faria S, Raut CP, Evans DB, Wolff RA, Crane CH, Dubrow RA, Charnsangavej C. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging 31(5):568-574, Sep-Oct, 9/2006. e-Pub 2/2006. PMID: 16465578.
80. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035-1046, 8/2006. PMID: 16865597.
81. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24(4):3953-3958, 8/2006. PMID: 16921048.
82. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Levy LB, Ellis LM, Crane CH. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 29(3):219-224, 6/2006. PMID: 16755173.
83. Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delclos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA, Janjan N. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol 29(3):232-9, 6/2006. PMID: 16755175.
84. Li D, Frazier M, Evans DB, Hess KR, Crane, CH, Jiao L, Abbruzzese JL. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 24(11):1720-1728, 4/2006. PMID: 16520463.
85. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24(7):1145-1151, 3/2006. PMID: 16505434.
86. Bedrosian I, Giacco G, Pederson L, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Delclos M, Crane CH, Janjan N, Skibber JM. Outcome after curative resection for locally recurrent rectal cancer. Dis Colon Rectum 49(2):175-182, 2/2006. PMID: 16392024.
87. Beddar AS, Krishnan S, Briere TM, Wang X, Delclos ME, Ballo MT, Das P, Gould S, Horton JL, Crane CH. The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators. Radiother Oncol 78(2):207-212, 2/2006. PMID: 16376445.
88. Wong AA, Delclos ME, Wolff RA, Evans DB, Abbruzzese JL, Tamm EP, Xiong HQ, Ho L, Crane CH. Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol 28(3):227-333, 6/2005. PMID: 15923793.
89. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 23(13):3094-3103, 5/2005. PMID: 15860869.
90. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23(6):1237-1244, 2/2005. PMID: 15718321.
91. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA, Evans DB. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8(8):935-949; discussion 949-950, 12/2004. PMID: 15585381.
92. Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, Hoff PM, Lin E, Eng C, Wong A, Janjan NA, Feig BW. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys 60(4):1098-1105, 11/2004. PMID: 15519780.
93. Bedrosian I, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Delclos M, Crane C, Janjan N, Skibber JM. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J Gastrointest Surg 8(1):56-62; discussion 62-63, 2004. PMID: 14746836.
94. Crane CH, Skibber JM, Birnbaum EH, Feig BW, Singh AK, Delclos ME, Lin EH, Fleshman JW, Thames HD, Kodner IJ, Lockett MA, Picus J, Phan T, Chandra A, Janjan NA, Read TE, Myerson RJ. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 57(1):84-89, 9/2003. PMID: 12909219.
95. Crane CH, Mason K, Janjan NA, Milas L. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol 26(4):S81-S84, 8/2003. PMID: 12902862.
96. Papagikos M, Crane CH, Skibber J, Janjan NA, Feig B, Rodriguez-Bigas MA, Hung A, Wolff RA, Delclos M, Lin E, Cleary K. Chemoradiation for adenocarcinoma of the anus. Int J Radiat Oncol Biol Phys 55(3):669-678, 3/2003. PMID: 12573754.
97. Hung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, Feig B, Skibber J, Janjan N. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 97(5):1195-1202, 3/2003. PMID: 12599225.
98. Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, Rodriguez-Bigas MA, Wolff RA, Ellis LM, Delclos ME, Lin EH, Janjan NA. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97(5):517-524, 1/2003. PMID: 12518377.
99. Esnaola NF, Cantor SB, Johnson ML, Mirza AN, Miller AR, Curley SA, Crane CH, Cleeland CS, Janjan NA, Skibber JM. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. J Clin Oncol 20(21):4361-4367, 11/2002. PMID: 12409336.
100. Crane CH, MacDonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, Wong A, Delclos M, Charnsangavej C, Janjan NA. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 53(4):969-974, 7/2002. PMID: 12095564.
101. Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20(10):2537-2544, 5/2002. PMID: 12011133.
102. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52(5):1293-1302, 4/2002. PMID: 11955742.
103. Crane CH, Antolak J, Rosen I, Forester K, Evans DB, Wolff RA, Abbruzzese JL, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Papagikos MA, Janjan NA. Prospective study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30(3):123-132, 3/2002.
104. Janjan N, Crane C, Delclos M, Ballo M. Brachytherapy for locally recurrent soft-tissue sarcoma. Am J Clin Oncol 25(1):9-15, 2/2002. PMID: 11823688.
105. Taylor N, Crane C, Skibber J, Feig B, Ellis L, Vauthey JN, Hamilton S, Cleary K, Dubrow R, Brown T, Wolff R, Hoff P, Sanfilippo N, Janjan N. Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal. Int J Radiat Oncol Biol Phys 51(3):741-747, 11/2001. PMID: 11597817.
106. Michalski J, Purdy JA, Gaspar L, Souhami L, Ballow M, Bradley J, Chao CK, Crane C, Eisbruch A, Fallowil D, Forster K, Fowler J, Gillin MT, Graham ML, Harms WB, Huq MS, Kline RW, Mackie TR, Mukherji S, Podogorsak EB, Roach M, Ryu J, Sandler H, Schultz CJ, Schell M, Verhey LJ, Vicini F, Winter KA. Radiation Therapy Oncology Group. Research Plan 2002-2006. Image-Guided Radiation Therapy Committee. Int J Radiat Oncol Biol Phys 51(3) (Suppl 2):60-65, 10/2001. PMID: 11641018.
107. Wang XS, Janjan NA, Guo H, Johnson BA, Engstrom MC, Crane CH, Mendoza TR, Cleeland CS. Fatigue during preoperative chemoradiation for resectable rectal cancer. Cancer 92(4):1725-1732, 9/2001. PMID: 11598894.
108. Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys 51(3):19-27, 9/2001. PMID: 11641011.
109. Sanfilippo NJ, Crane CH, Skibber J, Feig B, Abbruzzese JL, Curley S, Vauthey JN, Ellis LM, Hoff P, Wolff RA, Brown TD, Cleary K, Wong A, Phan T, Janjan NA. T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. Int J Radiat Oncol Biol Phys 51(1):176-183, 9/2001. PMID: 11516868.
110. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24(2):107-112, 4/2001. PMID: 11319280.
111. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8(2):123-132, 3/2001. PMID: 11258776.
112. Crane CH, Janjan NA, Abbruzzese JL, Curley S, Vauthey J, Sawaf HB, Dubrow R, Allen P, Ellis LM, Hoff P, Wolff RA, Lenzi R, Brown TD, Lynch P, Cleary K, Rich TA, Skibber J. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys 49(1):107-116, 2001. PMID: 11163503.
113. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29(2):9-18, 2001. PMID: 11560155.
114. Phan TP, Crane CH, Janjan NA, Vrdoljak E, Milas L, Mason KA. WR-2721 Reduces intestinal toxicity from concurrent gemcitabine and radiation treatment. Int J Pancreatol 29(1):45-50, 2001.
115. Hoff PM, Janjan N, Saad ED, Skibber J, Crane C, Lassere Y, Cleary KR, Benner S, Randolph J, Abbruzzese JL, Pazdur R. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 18(20):3529-3354, 10/2000. PMID: 11032595.
116. Janjan NA, Crane CN[sic], Feig BW, Cleary K, Dubrow R, Curley SA, Ellis LM, Vauthey J, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 47(3):713-718, 6/2000. PMID: 10837955.
117. Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 18(4):860-867, 2/2000. PMID: 10673529.
118. Narayan K, Crane CH, Kleid S, Hughes PG, Peters LJ. Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with definitive radiotherapy: for some or for all? Head Neck 21(7):606-613, 10/1999. PMID: 10487947.
119. Shelton CH, Levine PA, Crane CH, Rich TA. Irradiation of recurrent respiratory papillomatosis causing spinal cord compression. Am J Otolaryngol 20(3):180-183, 5/1999. PMID: 10326756.
120. Steadham AM, Liu HH, Crane CH, Janjan NA, Rosen II. Optimization of beam orientations and weights for coplanar conformal beams in treating pancreatic cancer. Med Dosim 24(4):265-271, 5/1999. PMID: 10643735.
121. Crane CH, Schneider BF. Occult carcinoma discovered after simple hysterectomy treated with postoperative radiotherapy. Int J Radiat Oncol Biol Phys 43(5):1049-1053, 3/1999. PMID: 10192354.
122. Crane CH, Clark MM, Bissonette EA, Theodorescu D. Prospective evaluation of the effect of ionizing radiation on the bladder tumor-associated (BTA) urine test. Int J Radiat Oncol Biol Phys 43(1):73-77, 1/1999. PMID: 9989516.
123. Crane CH, Rich TA, Read PW, Sanfilippo NJ, Gillenwater JY, Kelly MD. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 39(3):681-686, 10/1997. PMID: 9336150.

Invited Articles

1. Ko AH, Crane CH. Radiation therapy in operable and locally advanced pancreatic cancer. J Natl Compr Canc Netw 8(9):1022-1031, 9/2010. PMID: 20876542.
2. Das P, Crane CH. Predictors of Outcome for Anal Cancer. Radiat Med Rounds 1:391-398, 6/2010.
3. Crane CH, Varadhachary G, Pisters PWT, Evans DE, Wolff RA. Future chemoradiation strategies in pancreatic cancer. Semin Oncol 34(4):334-346, 8/2007.
4. Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB. The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol 20(2):365-382, 4/2006. PMID: 16549333.

Editorials

1. Crane, CH and Willett, CW. Stereotactic radiotherapy for pancreatic cancer? Cancer 115(3):468-472, 2/2009. PMID: 19117338.
2. Crane CH. The promise and pitfalls of organ preservation for locally advanced rectal cancer. Ann Surg Oncol 13(3):288-290, 2006.
3. Crane CH, Sargent DJ. Substitution of oral fluoropyrimidines for infusional 5-FU with radiotherapy: How much data do we need? J Clin Oncol 22(15):1-4, 2004.

Grant & Contract Support

Title: Radiation Therapy Oncology Group, Gastrointestinal Cancer Committee Chair Agreement
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: Wally Curran
Duration: 7/1/2010 - 12/31/2014
 
Title: Optimizing Proton Therapy Optimizing Proton Therapy - Project 2: Improving the Therapeutic Ratio of Proton Radiation Therapy in Challenging Clinical Sites.
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Tom Delaney
Duration: 9/25/2008 - 7/31/2014
 
Title: Optimizing Proton Radiation Therapy
Funding Source: NCI/NIH
Role: Collaborator
Principal Investigator: DeLaney/Mohan
Duration: 9/25/2008 - 7/31/2013
 
Title: Phase I trial of preoperative radiotherapy with concurrent erlotinib, bevacizumab and capecitabine for locally advanced rectal cancer
Funding Source: Genentech
Role: CO-PI and Mentor
Principal Investigator: Prajnan Das
Duration: 1/1/2007 - 1/1/2011
 
Title: Phase I trial of radiotherapy and concurrent erlotinib, bevacizumab and gemcitabine for locally advanced pancreatic cancer
Funding Source: Genentech
Role: CO-PI and Mentor
Principal Investigator: Sunil Krishnan
Duration: 1/1/2007 - 1/1/2011
 
Title: Multi-institutional Phase II Study of Cetuximab, Gemcitabine and Oxaliplatin followed by Capecitabine, Cetuximab and Radiotherapy in Locally Advanced Pancreatic Cancer
Funding Source: Bristol Meyers Squibb
Role: Principal Investigator
Duration: 1/1/2005 - 1/1/2009
 
Title: Principal Investigator, Phase I Study of Concurrent Bevacizumab, Capecitabine, and Radiotherapy in Locally Advanced Pancreatic Cancer
Funding Source: Genentech
Role: Principal Investigator
Duration: 1/1/2003 - 1/1/2006
 
Title: Phase I Trial of Concurrent Weekly CPT-11, 5-FU, Radiotherapy and Celebrex for Patients presenting with Metastatic Colorectal Cancer
Funding Source: Pharmacia
Role: Principal Investigator
Duration: 1/1/2002 - 1/2004
 
Title: Advancing Cancer Treatment Through the Combination of New Radiosensitizers and Biologic Agents with more Advanced Radiation Delivery: An Integrated
Funding Source: Radiological Society of North America
Role: Principal Investigator
Duration: 7/2000 - 7/2002
 
Title: A phase I study of concomitant Gemzar (gemcitabine) and rapid-fractionation external beam radiation therapy with 3-D conformal (intensity modulated) treatment planning for patients with unresectable adenocarcinoma of the pancreatic head
Funding Source: PRS Children’s Art Project Award
Role: Principal Investigator
Duration: 2/2000 - 2/2002

Last updated: 7/14/2014